We are live on ! Find out more
EVGN icon

Evogene

16 hedge funds and large institutions have $10.8M invested in Evogene in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.3% less ownership

Funds ownership: 2.92%2.62% (-0.3%)

6% less funds holding

Funds holding: 1716 (-1)

29% less capital invested

Capital invested by funds: $15.2M → $10.8M (-$4.43M)

88% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 8

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.32%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
1
Reduced
8
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
WRF
1
Waddell & Reed Financial
Kansas
$4.14M -$57.5K -3,850 -1%
UBS Group
2
UBS Group
Switzerland
$2.08M -$62K -4,149 -3%
Goldman Sachs
3
Goldman Sachs
New York
$1.13M -$40.3K -2,700 -4%
SM
4
Senvest Management
New York
$630K
CI
5
Clal Insurance
Israel
$591K -$882K -59,036 -100%
MCM
6
Moon Capital Management
New York
$556K
Bank of America
7
Bank of America
North Carolina
$494K
PF
8
Phoenix Financial
Israel
$397K
AIM
9
ARK Investment Management
Florida
$345K +$26.8K +1,796 +9%
JP Morgan Chase
10
JP Morgan Chase
New York
$335K -$1.41K -94 -0.4%
MIH
11
Meitav Investment House
Israel
$30K -$77.9K -5,213 -73%
Jane Street
12
Jane Street
New York
$19K -$34.5K -2,312 -65%
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$15K
Citigroup
14
Citigroup
New York
$12K
Barclays
15
Barclays
United Kingdom
$1K
Citadel Advisors
16
Citadel Advisors
Florida
-$31K -1,938 Closed
Morgan Stanley
17
Morgan Stanley
New York
-$14.9K -1,000 -100%

EVGN Hedge Fund Activity: Q4 2019 in Review

16 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2019, worth a combined $10.8M — down 29% from $15.2M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of EVGN and 0 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 1 added.

The largest buyer was ARK Investment Management, adding an estimated $26.8K. The largest seller was Clal Insurance, cutting an estimated $882K.

  • 16 institutional investors held Evogene (EVGN) as of Q4 2019, down from 17 in Q3 2019.
  • Funds reported $10.8M of Evogene stock for Q4 2019, down 29% quarter-over-quarter.
  • 0 funds opened new Evogene positions in Q4 2019 and 1 closed out, a net change of -1 holder.
  • The largest Evogene buyer in Q4 2019 was ARK Investment Management, an estimated $26.8K added.
  • The largest Evogene seller in Q4 2019 was Clal Insurance, an estimated $882K sold.

Based on aggregated 13F filings for Q4 2019.